Biologics CDMO market to grow by US$10.63b in 2028

This growth is driven by the increasing demand for specialised expertise.

The global biologics contract development and manufacturing organization (CDMO) market size is forecasted to grow by US$10.63b from 2024 to 2028 with a growth rate of 10.46%, according to Technavio.

This growth will be driven by the increasing demand for specialised expertise and advanced technology in producing complex biological medicinal products.

Niche CDMOs and biopharmaceutical CDMOs are leading the production of biologics, such as recombinant proteins and monoclonal antibodies.

Moreover, the mammalian segment holds a significant market share due to the increasing use of mammalian cells in producing therapeutic proteins for various diseases.

However, the market faces challenges in producing small and large molecules, including biologics, monoclonal antibodies, and vaccines.

Furthermore, the market is also challenged by capacity utilisation as it plays a significant role in manufacturing various therapeutics, particularly biological drugs, due to the intricate production process.

Approximately 35% of CDMOs encounter minor capacity utilisation constraints during manufacturing, whilst 20% experience moderate to major constraints.